Leerink Partnrs Comments on Aligos Therapeutics, Inc.’s FY2028 Earnings (NASDAQ:ALGS)

Aligos Therapeutics, Inc. (NASDAQ:ALGSFree Report) – Stock analysts at Leerink Partnrs issued their FY2028 earnings estimates for Aligos Therapeutics in a research note issued to investors on Monday, February 5th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post earnings of $0.86 per share for the year. The consensus estimate for Aligos Therapeutics’ current full-year earnings is ($1.66) per share.

Aligos Therapeutics Stock Down 1.9 %

Shares of ALGS stock opened at $0.68 on Wednesday. The company’s fifty day simple moving average is $0.68 and its 200-day simple moving average is $0.75. The firm has a market cap of $50.73 million, a PE ratio of -0.36 and a beta of 2.19. Aligos Therapeutics has a 12 month low of $0.54 and a 12 month high of $1.90.

Institutional Trading of Aligos Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Aligos Therapeutics by 1.6% in the third quarter. Vanguard Group Inc. now owns 1,010,617 shares of the company’s stock worth $755,000 after purchasing an additional 15,905 shares in the last quarter. Newtyn Management LLC lifted its position in shares of Aligos Therapeutics by 2.2% in the third quarter. Newtyn Management LLC now owns 920,000 shares of the company’s stock worth $687,000 after purchasing an additional 20,000 shares in the last quarter. Royal Bank of Canada raised its position in Aligos Therapeutics by 1,779.4% during the second quarter. Royal Bank of Canada now owns 840,393 shares of the company’s stock worth $816,000 after acquiring an additional 795,678 shares in the last quarter. Geode Capital Management LLC raised its position in Aligos Therapeutics by 28.4% during the second quarter. Geode Capital Management LLC now owns 256,592 shares of the company’s stock worth $249,000 after acquiring an additional 56,734 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. bought a new stake in Aligos Therapeutics during the second quarter worth $30,000. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

(Get Free Report)

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB).

Featured Articles

Earnings History and Estimates for Aligos Therapeutics (NASDAQ:ALGS)

Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.